The quantitation of nicotine metabolites as biomarkers of tobacco exposure in lung cancer cases has confirmed that the relationship of CYP2A6 genotype to lung cancer risk is mediated by the effect of variation in nicotine metabolism on smoking dose, as illustrated in Figure 2. The gene discussed is CYP2A6; the disease is lung carcinoma.